This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Sialic acid-binding Ig-like lectin 7.
Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.
Human | |
---|---|
Gene Name: | SIGLEC7 |
Uniprot: | Q9Y286 |
Entrez: | 27036 |
Belongs to: |
---|
immunoglobulin superfamily |
Adhesion inhibitory receptor molecule 1; adhesion inhibitory receptor molecule 1, siglec-7; AIRM1; AIRM-1; AIRM1QA79 membrane protein; CD328 antigen; CD328; CDw328; D-siglec; p75; p75/AIRM1; QA79; sialic acid binding Ig-like lectin 7; sialic acid binding immunoglobulin-like lectin 7; sialic acid-binding Ig-like lectin 7; Siglec7; Siglec-7
Mass (kDA):
51.143 kDA
Human | |
---|---|
Location: | 19q13.41 |
Sequence: | 19; NC_000019.10 (51142260..51153526) |
Predominantly expressed by resting and activated natural killer cells and at lower levels by granulocytes and monocytes. High expression found in placenta, liver, lung, spleen, and peripheral blood leukocytes.
Membrane; Single-pass type I membrane protein.
You have probably heard of SIGLEC7. But what exactly is this marker? Why is it important? What is it good for? Let's see! This article will help you discover the many advantages of SIGLEC7 markers as well as their best uses. Here's an even closer look. - Siglec9 And SIGLEC7 Are Both Essential
Antibodies to Siglec-9 markers may be effective in fighting cancer. The antibody will target interactions that occur with this immune-checkpoint and be highly selective and specific. The research team is currently evaluating the potential utility of the Siglec-9 antibody for cancer immunotherapy. The antibody will be approved for clinical use in the following year. There are many ways to use the antibody. It is currently available as three versions:
Siglec-9, a common cancer marker, is widely expressed. It has been associated with improved survival in patients suffering from non-small-cell pulmonary cancer. It regulates T cell activation. The higher survival rate of cancer patients with Siglec-9 expression (SNP rs16988910) is associated with Siglec-9. Siglec-9 tumors also inhibit neutrophil activation as well as macrophage polarization. It is still unclear what Siglecs do to macrophages.
A study conducted on eight mammalian species found that Siglec-9 gene levels are associated with lifespan. However, this is not definitive as the lifespan of the species varies. Siglec E-/ mice lived an average of 17% less than the WT group. The number of cells that express the CD33rSiglec gene in Siglec -E-/ mice was not reduced when heterologous membranes were added to Freund's adjuvant.
The research was done using recombinant human Siglec-9. It was found that the antigen was highly specific for human Siglec-9. Moreover, the study included anti-hSiglec-9 mAbs. These reagents were provided by the company for use within the immunology industry. These antibodies are available at tebu-bio. These antibodies are also useful in the detection of various types of cancer.
The active form of Siglec depends on several parameters. Its density, relative affinity for ligands, and the rate of recycling of ligands may all affect its activity. The inhibitors could be effective in preventing Siglec mediated tumor cell growth. It remains a significant hurdle in pharmaceutical development. The Siglec-9 marker could be an ideal choice to treat cancer.
Clinical trials demonstrated that the Siglec-9 genetic gene was expressed in mice by adding human Siglec-9 DNA. The mice were then immunized and harvested for hybridoma development. After the mice were injected in with the human Siglec-9 genetic material, they were subject to ELISA to determine the level of antibodies against human-Siglec-9. Interestingly, these mice produced antibodies to human-Siglec-9 protein, and the polyclonal antibody titer remained high even after subsequent injections. The hybridomas were also gated using siglec-9GFP-GFP-overexpressing K562 cells.
The protein is found within many organs, such as the brain. It is an essential regulator for phagocyte homeostasis. It inhibits the oxidative burst of macrophages on LPS. It also plays a role in the immune system, where its absence results in an overproduction of reactive species. This enzyme blocks the production of ROS. When this enzyme is impaired, the cells are prone to inflammatory diseases, which include cancer and neurodegenerative diseases.
The Siglec-9 gene has been associated with many cancer-related diseases. However, their function is unknown. Cancer cells produce cell surfaces that are heavily sialylated. They also bind with the Siglecs (neutrophils and natural killer cell) to evade the immune response. Siglecs' role in cancer immunotherapy is still unknown.
Synthetic genes produce the recombinant antiSiglec-9 anti-Siglec-9 antibodies. This monoclonal anti-Siglec-9 antibody is purified, and the results are analyzed by Western blot analysis and SDS–PAGE. These results are promising for further development of drugs and biotherapies targeting Siglec-9. These antibodies are useful in many areas of cancer research. Scientists can use these antibodies to discover new ways of diagnosing and treating cancer.
This siglec-7 marker consists of polypeptides that have varying sequences and are expressed in cells. Mutants have multiple amino acid residues. This sequence is referred to as DYSMH CDR2 and CDR3. All of these proteins are known to be present in human cells. This marker can be used in order to identify different types or cancer cells, and to help identify the type tumor cells present in a specific tissue sample.
Siglec-7, a competitive antigen that can recognize Siglec-9 and Siglec-7 in the same cell types, is called a Siglec-7 marker. Competition can occur with antibodies whose heavy and light chains contain variable regions. These antibodies can still be competitive, so competition studies are possible. These antibodies can be used to perform western blotting as well as BIACORE.
The antibody binds human Siglec-7 & -siglec-9 polypeptides and neutralizes their inhibitory activities. The antibody neutralizes inhibitory action of human Siglecs on human monocytes. It also works in human dendritic cell, NK and NK cells. For this reason, Boster Bio has published a patent for its antibody against human Siglec-7.
Boster Bio's Siglec-7 marker can be used in a wide variety of applications. Antibodies targeting Siglec-7 have high affinity for human sialic. Anti-Siglec antibodies are highly selective, and can detect the presence of cancer cells in a specific tissue sample. They can detect Siglec-7 and help diagnose and treat illnesses.
A new study has identified the best use of the Siglec-7 marker for NK cells in cancer. These antibodies can be used for cancer immunotherapy. They may also increase the cytotoxicity in tumor cells. Siglec-9 regulates activation of primary NK cell and protects cancer cells against being destroyed. It is therefore important to recognize tumor cells expressing Siglec-7.
Standard immunocytotoxicity assays can detect antibodies against Siglec-7. In vitro cytotoxicity assays can also determine if an anti-Siglec antibody will kill a target cell expressing sialic acid ligand. You can use primary NK cell lines to conduct the cytotoxicity test. Incubation at 37°C overnight is recommended.
The Siglec-7 marker is increasingly being used in gene therapy research. It is widely used in cancer immunotherapy. Because Siglec-7 is a polypeptide that is expressed in most cancer cells, the antibody can detect the expression of the gene in cancer cells. However, Siglec-7 is not a perfect marker for research. These antibodies still allow for the identification of the gene or trait of interest with high precision.
Antibodies for antiSiglec markers are made to bind to the appropriate polypeptides on human NK cells' surfaces. They offer several benefits, including their pharmacological and therapeutic properties. Anti-Siglec antibodies block Siglec-7-7 expression and inhibit NK cell activity. These antibodies bind naturally to Siglec-7, Siglec-9.
Other studies have supported the hypothesis that siglec/sialoglycan has an effect on cancer, autoimmunity, and other diseases. Sialidase (the NK cell killing enzyme Sialidase) was found to inhibit the Siglec/sialoglycan. It has been linked with a slowing of HIV disease progression. This study demonstrates the importance of this molecule for the treatment and prevention of cancer and autoimmunity.
These results indicate that the ability to deal with cellular stresses in primary fibroblasts is crucial for longevity in human cell lines. The study also found a correlation between the lifespans of eight mammalian species and the number Siglec genes within primary fibroblasts. In humans, Siglecs have been shown to correlate with longevity and metabolic rate. The number CD33rSIGLEC-related genes in mice positively correlates to maximum life expectancy.
PMID: 10567377 by Nicoll G., et al. Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.
PMID: 10499918 by Falco M., et al. Identification and molecular cloning of p75/AIRM1, a novel member of the sialoadhesin family that functions as an inhibitory receptor in human natural killer cells.